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dromal AD. We calculated the potential future costs of expanding the number of positron emission
tomography (PET) and cerebrospinal fluid (CSF) tests in the United Kingdom.
Methods: We conducted a focused literature review and consulted experts to obtain information on
the current use of PET and CSF to diagnose prodromal AD, staffing and equipment requirements for
these tests, and associated costs.
Results: We estimate annual costs of 100,000 extra amyloid PET scans and 100,000 extra CSF tests
at £113 million and £48 million, respectively; these costs are likely to be higher in the first year.
Discussion: The budgetary impacts are not insignificant but are small in comparison to the likely
market price of any disease-modifying treatments or to the probable costs of missed or inaccurate
diagnosis.
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commons.org/licenses/by-nc-nd/4.0/).dividuals without evidence for AD to potentially harmful
medications. It is also likely that disease-modifying treat-
ments will have maximum effects when given early in the
disease process. The emergence of disease-specific bio-
markers, and the methods to demonstrate amyloid b (Ab) pa-
thology, in particular, provides a means for improving
diagnostic specificity. There is also now clear evidence
that biomarkers reflecting aspects of the disease process
become abnormal before onset of clinical symptoms [1–3].
This has paved the way for new diagnostic criteria and a
new research framework [4]. New criteria allow for diag-
nosis of AD before the onset of dementia, for example,
when patients have mild cognitive impairment (MCI), which
in the presence of amyloid biomarkers has variously been
termed prodromal AD [5] or MCI-AD [6].
While in due course, blood-based biomarkers may have
utility in prescreening or identifying individuals with brainimer’s Association. This is an open access article under the CC BY-NC-ND
Table 1
PET scan cost per year under three scenarios—additional 10,000, 100,000,
or 250,000 scans
PET scans
Number of tests per year and related
hypothetical costs
10,000 100,000 250,000
Tracer £9,000,000 £90,000,000 £225,000,000
Radiographer £666,500 £6,665,000 £16,662,500
Radiologist £345,000 £3,450,000 £8,625,000
Purchase of scanner £0 £8,750,000 £20,000,000
Servicing of scanner £0 £2,975,000 £6,800,000
Workstation and software £0 £280,000 £6,400,000
Hospital room £0 £875,000 £2,000,000
Total costs £10,011,500 £112,995,000 £285,487,500
PET, positron emission tomography.
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deposition today are amyloid positron emission tomography
(PET) scanning and cerebrospinal fluid (CSF) analysis [7].
Substantial studies are being conducted on the value of am-
yloid imaging in diagnosis of AD. In the United States, the
Imaging Dementia - Evidence for Amyloid Scanning study
is assessing whether amyloid PET helps clinicians diagnose
the cause of cognitive impairment in diagnostically uncer-
tain cases. In Europe, the Amyloid Imaging to Prevent Alz-
heimer’s Disease study aims to determine the value of Ab
imaging as a diagnostic and therapeutic marker.
As/when a disease-modifying therapy for AD is licensed
and evidence of brain Ab accumulation is required for pre-
scription, demand for amyloidPET/CSFwill expand consider-
ably, with implications for health-care provision. We assessed
the current costs of PET scans and CSF analyses for AD in the
United Kingdom (UK) and estimated potential future costs of
expanding the requirement for such diagnostic tests.
There are currently around 800,000 older people living
with dementia in the UK and around 200,000 new cases of
dementia annually [8]. AD accounts for around 72% of de-
mentia cases when mixed dementia is included in the AD
figures [9]. Extrapolating from US age-specific data [10],
prevalence of MCI in the UK may be 1.2 million, with
annual incidence of 480,000. The study by Vos et al. [11] im-
plies an annual transition rate of 16% from all-cause MCI to
AD, with rates higher in those with prodromal AD (27%)
than in other forms (7%).2. Methods
We conducted a focused rapid literature review to find
studies of the current costs of amyloid PET and CSF testing
and their effectiveness and cost-effectiveness in diagnosis of
early stages of AD. We identified 55 articles published be-
tween January 2000 and December 2017 that included eco-
nomic modeling of treatment for MCI or AD. Six of these
studies had a specific focus on PETor CSF.We use these pre-
vious studies to help us locate and interpret our new cost esti-
mates. We consulted UK experts to obtain information on
current use of PET and CSF to diagnose early stages of AD,
staffing and equipment requirements for conducting these
tests, and associated costs. We estimated how those costs
might change if the number of tests increased substantially.3. Results
3.1. PET scanning
PET scanning is a nuclear imaging technique involving in-
jection of a radiotracer; imaging using a PET/CTor occasion-
ally PET/magnetic resonance imaging unit; and, for clinical
purposes, a visual read to determine positivity/negativity us-
ing predefined criteria. PET ligands approved for detection
of fibrillar Ab include florbetaben (Neuraceq), florbetapir
(Amyvid), and flutemetamol (Vizamyl). Althoughlicensed, no amyloid PET tracer is currently reimbursed in
the UK (or US); florbetapir is not clinically available in the
UK.
3.2. Costs of increasing capacity for PET scanning
We estimated costs to the UK National Health Service
(NHS) of conducting an additional 10,000, 100,000, or
250,000 PET scans per year for the diagnosis of AD at the
MCI stage.
Each of the 50 existing PET scanners in the UK supports
between 2000 and 4000 scans per year, most for oncology.
There are currently no data on current use for dementia diag-
nosis but this is clearly only a minority. An additional 10,000
scans per year would be unlikely to require purchase of
further scanners or other infrastructure and could be con-
ducted at marginal cost. However, an additional 100,000
scans or 250,000 scans per year would, we assume, require
around 35 or 80 extra scanners, respectively.
The marginal resources required for one scan comprise
around 80 minutes of radiographer time preparing the pa-
tient and conducting the scan, 15 minutes of consultant
time reporting the scan, the tracer, and administrative and
other support costs. The cost of radiographer (Band 6)
time, including salary on-costs, administrative support, and
annuitized cost of training, is £50 per hour [12]. The cost
of consultant radiologist time is £138 per hour.
The cost of the various amyloid tracers varies but is
approximately £900 excluding VAT. This cost might fall if
there is a large increase in the number of amyloid scans
because of economies of scale, but here we assume that
cost would not fall significantly with expansion. However,
in the case of 100,000 or more extra scans per year, we con-
ducted sensitivity analysis assuming that cost falls to £500.
The estimated overall cost of 10,000 extra PET scans for
AD annually is £10.0 million (Table 1). This includes costs
of staff time (£1 million) and the tracer (£9 million) but does
not allow for increase in any other resources on the assump-
tion that these scans could be undertaken at marginal cost.
The purchase price of a new PET/CT scanner is around
£1.3-£1.9 million excluding VAT. We assume an average
Table 2
CSF first-year cost per year under three scenarios—additional 10,000,
100,000, or 250,000 tests per year (including the first-year cost of specialist
nurse training)
CSF process
Number of tests per year and related hypothetical
costs
10,000 100,000 250,000
Nurses £2,077,350 £20,773,500 £51,933,750
Equipment £350,000 £3,500,000 £8,750,000
Hospital room £250,000 £2,500,000 £6,250,000
CSF analysis £2,000,000 £20,000,000 £50,000,000
Nurses training £1,654,550 £16,545,500 £41,363,750
Total costs £6,331,900 £63,319,000 £158,297,500
CSF, cerebrospinal fluid.
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average lifetime of a scanner) at an interest rate of 3.5% is
around £250,000. The annual cost of servicing a PET scan-
ner is around £85,000. The annual opportunity cost of 35
scanners is, therefore, around £11.7 million and of 85 scan-
ners is £26.8 million.
The cost of a workstation required for reporting PET
scans is around £30,000 and the cost of the software is
around £10,000. If these have a lifetime of 5 years, their
annual cost is around £8000. A hospital room will be
required for the scanner and a room for preparation of pa-
tients for scanning, for which we assume £25,000 per year.
We estimated that each scanner needs two to three full-
time radiographers to provide the service. The annual cost
for an average of 2.5 full-time equivalent radiographers is
around £200,000.
The overall annual cost per 3000 additional PET scans
(the assumed annual output of one scanner) is estimated at
£3.2 million or £1130 per scan. These figures would be
£2.1 million or £730 per scan if the price of the tracer fell
to £500. This includes the costs of purchasing and servicing
the scanner, the tracer, staff (including annuitized training
costs), premises, and IT and administrative support.
The overall cost of 100,000 extra PET scans is estimated
at £113 million per year. The equivalent annual estimate for
250,000 extra PET scans is £285million (Table 1). If the cost
of the tracer fell to £500, overall annual costs would be £73
million for 100,000 extra PET scans and £185 million for
250,000 extra scans.3.3. CSF testing
CSF provides a means for evaluating several of the hall-
mark proteins involved in AD, in particular, Ab1-42 and tau/
p-tau. A meta-analysis by Olsson et al. [13] shows that Ab1-
42 is depressed and tau is elevated in AD. CSF measures are
now included in both new diagnostic criteria and research
frameworks. CSF sampling involves lumbar puncture (LP)
by a suitably trained professional (physician assistant or
nurse); collection and storage of CSF in a standardized
manner; and quantification of proteins of interest in an ac-
credited laboratory.3.4. Costs of increasing capacity for CSF testing
We estimated costs to the NHS of providing an additional
10,000, 100,000, and 250,000 CSF tests per year for diag-
nosis of AD. While we have not found firm data on how
many CSF tests are currently conducted for dementia, fewer
than 2000 are conducted in the UK annually.
LP could be undertaken by a physician assistant or
specially trained nurse (Band 6 or 7). We estimate that
each nurse could undertake two LPs per day (450 per
year). This means that 22.25 full-time equivalent nurses
would be required to conduct 10,000 LPs per year. The
annual cost of a Band 7 nurse is £93,364 at 2016/7 prices[12], including salary, salary on-costs, overheads, and annui-
tized costs of basic training. We assume that a Band 7 salary
may be necessary to recruit and retain nurses to conduct LPs.
We include annuitized costs of basic training because an in-
crease would be required in the total number of NHS nurses.
Annual cost of 22.25 full-time equivalent nurses would be
£2,077,350 for 10,000 CSFs (Table 2). Costs for other scales
of activity are given in Table 2.
Equipment required for LP (needles, sample collection
tubes) costs around £35. The opportunity cost of the hospital
room used for LP is arguably included in the overall cost per
nurse since it includes capital overheads, but since the
amount included may be insufficient, an extra £25 is
assumed. The total for room and equipment amounts to
£0.6 million for 10,000 patients, £6.0 million for 100,000 pa-
tients, and £15.0 million for 250,000 patients.
Analysis of the CSF is estimated to cost £200 per case,
including annuitized cost of training for analysts. Hence, to-
tal cost for 10,000 CSF samples is £2,000,000; for 100,000
CSF samples, £20,000,000; and for £250,000 CSF samples,
£50,000,000. New analysis machines may be needed, but we
expect that deployment of new machines would be cost
neutral since they would reduce operator time.
We assume that, at the outset, 50 nurses would be offered
specialist training to undertake LPs. This allows for some
nurses working part-time and for a reasonable distribution
of additional LP staff across the country. Specialist training
would take 3 months. Salary costs of the nurses would be
£1,167,050. If the training cost including travel costs is
£150 per day, the direct cost would be £487,500 for 50
nurses. Total training cost for 50 nurses for conducting an
additional 10,000 CSFs per year would therefore be
£1,654,550. Total cost of training for 500 nurses for
100,000 additional CSFs would be £16.6 million; for 1250
nurses (for 250,000 additional CSFs), it would be £41.4
million.
Total first-year costs for 10,000 CSF tests would be £6.3
million including specialist training for nurses conducting
LPs (Table 2). Total first-year costs for 100,000 CSF tests
would be £63.3 million including specialist training or
£158.3 million for 250,000 tests. These estimates do not
Table 3
CSF cost per year under three scenarios—additional 10,000, 100,000, or
250,000 tests per year (including the second and subsequent year cost of
specialist nurse training)
CSF process
Number of tests per year and related hypothetical
costs
10,000 100,000 250,000
Nurses £2,077,350 £20,773,500 £51,933,750
Equipment £350,000 £3,500,000 £8,750,000
Hospital room £250,000 £2,500,000 £6,250,000
CSF analysis £2,000,000 £20,000,000 £50,000,000
Nurses training £165,455 £1,654,550 £4,136,375
Total costs £4,842,805 £48,428,050 £121,070,125
CSF, cerebrospinal fluid.
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analysis.
If the average period during which each nurse conducts
LPs is 10 years, five additional nurses would need to be
trained each year for additional 10,000 LPs, and overall
cost per year after the first year would be £4.8 million. For
larger increases in LPs, overall cost would multiply (see
Table 3). This does not allow for any real increase in nurses’
salaries, which may be expected.4. Discussion
4.1. Context
Supporting people with dementia is costly. Total cost in
England in 2015 is estimated to be £24.2 billion, 16% of
which was for health care, 42% social care, and 42% unpaid
care by families and friends [8]. New projections to 2040
suggest that the number of older people in England with de-
mentia will more than double by 2040 and costs more than
treble in real terms [14].
Currently available pharmaceutical treatments and stan-
dard care can improve the overall health and well-being
for people with AD and their carers [3,15]. However,
disease-modifying treatments—of which none are currently
marketed—offer the possibility of achieving greater im-
provements in health and well-being, while reducing the
costs of support. This is especially important given projec-
tions of rapidly escalating costs as the population ages. For
new compounds to be most effective, there is a need for early
and accurate identification of people most at risk of devel-
oping AD to provide prompt access to treatment.
4.2. Summary of findings
We estimated the current UK costs of twomolecular diag-
nostic tests currently available for AD—PET scans and CSF
analyses—and the costs of expanding the number of such
tests.
Estimated overall costs of 100,000 extra PET scans,
requiring an additional 35 scanners, is £113 million per
year, which equates to approximately £1000 per scan.Total first-year costs for 100,000 CSF tests would be
£63.3 million, including cost of specialist training for nurses
conducting the LPs but not the cost of training more techni-
cians to conduct CSF analyses. Cost in subsequent years
would be lower since fewer nurses would require specialist
training. Overall, cost in subsequent years would be around
£500 per test.4.3. Previous economic studies
A systematic review of economic evaluations of interven-
tions for early diagnosis of AD and related disorders by
Handels et al. [16] found few such studies: only eight
decision-analytic modeling studies and one trial-based eval-
uation. Although there have been a few subsequent studies,
the evidence base in this area remains sparse.
Handels et al. [17] modeled potential economic gains
from a “perfect” CSF biomarker allied to a hypothetical
disease-modifying treatment: the biomarker had greater
benefit when used to rule out AD (to prevent undertreatment)
than when confirming diagnosis (prevent overtreatment).
Cost per CSF test (£211 in the Netherlands) was based on
expert opinion, but no details were given of what this cost
covers. Handels et al. [18] used data merged from cohort
studies to examine the cost-effectiveness of adding CSF
testing to standard diagnostic procedures. CSF testing was
found to improve the accuracy of prognosis from MCI to
AD by 11% and was cost-effective. The additional cost of
adding LP to the usual diagnostic process was £432 per pa-
tient (based on figures from Sweden, 2015 prices).
Valcarcel-Nazco et al. [19] concluded from a modeling
study that use of CSF biomarkers was more cost-effective
than standard clinical diagnostic criteria in patients with
MCI and probably more cost-effective in patients with de-
mentia. However, from the information provided in the pa-
per, it is not possible to identify the cost per CSF test used
in the modeling.
Lee et al. [20] found that the sensitivity and dependency
of CSF biomarker analysis are affected by the prevalence of
AD in the population tested. Where AD prevalence after
clinical assessment and standard neuroimaging is low, anal-
ysis is unlikely to be cost-effective, but when it is higher than
15%, it is likely to be cost-saving. This result is therefore
linked to the extent of pre-CSF testing, with implications
for targeting of diagnostic tests.4.4. Implications
Given expected rapid growth in the number of people at
risk of developing AD and other dementias and the prospect
that there may soon be available new medications with po-
tential to prevent, delay, or slow down progression of these
conditions, it is highly likely that therewill be a need for sub-
stantial increases in PET and/or CSF diagnostic testing.
While the costs of each test may look modest in comparison
to other inputs to the care pathway, serious consideration
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and their effects on costs.
A large increase in diagnostic testing will require sub-
stantial increases in supply of key inputs to diagnostic testing
processes, particularly equipment and laboratory facilities,
tracers, skilled nursing, radiology staff, and premises. A
key question, therefore, is whether the supply of those re-
sources can be increased. There are already shortages of
both nurses and radiologists in the UK [21,22]; increasing
supply would take at least a few years given the training
required and the low likelihood of recruiting sufficiently
from abroad. The supply of radiotracers may not be able to
respond to demand, which could push up prices at least
initially, although in time the price could fall due to
economies of scale. Our cost estimates do not allow for
effects of possible supply constraints.
A related consideration is whether the accuracy of testing
would be maintained at its present level after substantial
expansion in the number of tests. Would greater scale
improve accuracy through accumulation of experience or
would it make it harder to assure quality if the number of
centers carrying out tests multiplied? The finding by Lee
et al. [20] that the cost-effectiveness of diagnostic testing
is linked to underlying prevalence of AD in the group tested
suggests a need to consider offering tests only to people who
screen positive on initial screening (e.g., mini-mental state
examination). This would not be an issue if testing was
offered only to people with MCI, as assumed here, since
they have a high probability of having underlying AD. How-
ever, with a wider screening approach, a two-step diagnostic
process could be considered in which initial screening was
an integral part of the care pathway.
Budgetary impacts of a substantially expanded number of
PET and CSF tests are not insignificant. However, it needs to
be recognized that the costs of these diagnostic tests are
small in comparison to the likely market price of any new
disease-modifying treatments or to the probable costs of
missed or inaccurate diagnosis [23].
Our cost estimates are necessarily specific to the UK and
reflect the costs of labor, equipment, and laboratory testing
in the NHS. These costs are likely to differ substantially
across health-care settings and countries. Nonetheless, the
relative costs of CSF and PET imaging are likely to be
broadly similar, suggesting that CSF screening may be
more cost-effective, noting that LPs are contraindicated in
certain settings (e.g., anticoagulation), may be unacceptable
to some individuals, and thus, provision of both modalities
will be needed. Availability of blood tests to prescreen indi-
viduals at low risk of Ab pathology may also reduce
numbers of CSF/PET scans required.
A crucial question is whether there are cost-effectiveness
gains or better still actual cost savings, from increasing PET
scans or CSF tests. This obviously depends on assumptions
made about treatments offered following the tests: are those
symptomatic (as currently available) or disease-modifying(as currently under development)? We have not attempted
any such modeling here. The few previous studies which
have explored those wider economic questions have gener-
ally concluded that there is an economic case for diagnostic
testing, givenwhat is known and observed today but have not
factored in the possibility of unit cost increases or input sup-
ply constraints.
The availability of disease-modifying drugs for AD will
require major changes in how we approach the investigation
of patients with memory complaints, including significant
increased provision of molecular diagnostics. Our estimates
of the associated costs can inform discussion and planning of
future services.
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1. Systematic review: The authors reviewed the litera-
ture using traditional (e.g., MEDLINE, EMBASE,
OpenGrey) sources and relevant search terms (e.g.,
dementia, cost analysis, positron emission tomogra-
phy [PET], cerebrospinal fluid [CSF]). A few articles
examined the costs and cost-effectiveness of CSF
and PET in diagnosing Alzheimer’s disease. Those
most relevant are cited.
2. Interpretation: The estimated annual cost of 100,000
extra amyloid PET scans is £113 million per year and
of 100,000 extra CSF tests is £48 million (more in
first year).
3. Future directions: The prospect of new disease-
modifying treatments offered at the mild cognitive
impairment stage means that health services should
prepare for substantially increased diagnostic testing.
Key questions include whether the supply of key
resources required for PET or CSF can be increased
sufficiently; whether the accuracy of testing would
be maintained if there was substantial expansion in
testing; and whether PET or CSF should be offered
only to those screening positive on an initial screen.
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